Ascensia and Sava Partner to Commercialize Wearable Glucose Microsensor

Ascensia Diabetes Care has entered into a commercial and financing agreement with UK-based medical technology developer Sava Technologies to distribute its wearable glucose microsensor. Under the terms of the deal, Ascensia secured exclusive distribution rights, beginning in Europe, and made a strategic equity investment by leading Sava’s Series B funding round.

Details of the Wearable Microsensor Technology

The wearable platform is designed to track subcutaneous molecules and biomarkers in real time, starting with glucose monitoring. Sava states that its microsensor utilizes a more minimally invasive method compared to existing continuous glucose monitoring systems and has the capacity to provide broader physiological data. Additionally, the technology is intended to support wider health and disease monitoring beyond glucose over the longer term.

Upcoming Clinical Studies and Regulatory Goals

Sava plans to conduct a pivotal clinical study for the continuous glucose monitoring technology. The company aims to secure CE approval and release the device within 18 to 24 months for non-adjunctive use, which would allow insulin dosing without routine confirmatory tests. Distribution is planned through retail avenues and established reimbursement pathways, mirroring Ascensia’s primary blood glucose monitoring distribution network.

Leadership Perspectives on the Collaboration

Ascensia CEO Peter Bodlund noted that microsensors have the potential to transform the day-to-day monitoring experience for people with diabetes. By bringing together Sava’s technology with Ascensia’s diabetes expertise and commercial capabilities, the partnership seeks to address unmet needs in diabetes care.

• Ascensia secured exclusive European distribution rights and led Sava’s Series B funding round.
• Sava plans a pivotal clinical study and aims for CE approval within 18 to 24 months.
• The microsensor tracks subcutaneous molecules and biomarkers in real time, beginning with glucose.

Source: Medical Device Network